{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:41:06Z","timestamp":1781649666419,"version":"3.54.5"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T00:00:00Z","timestamp":1319673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00415-011-6278-4","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T09:37:48Z","timestamp":1319621868000},"page":"1019-1028","source":"Crossref","is-referenced-by-count":28,"title":["Stroke and Fabry disease"],"prefix":"10.1007","volume":"259","author":[{"given":"Miguel","family":"Viana-Baptista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,27]]},"reference":[{"key":"6278_CR1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","volume":"5","author":"A Fellgiebel","year":"2006","unstructured":"Fellgiebel A, M\u00fcller MJ, Ginsberg L (2006) CNS manifestations of Fabry\u2019s disease. Lancet Neurol 5:791\u2013795","journal-title":"Lancet Neurol"},{"key":"6278_CR2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International Collaborative Fabry Disease Study Group (2001) Safety and efficacy of recombinant human \u03b1-galactosidase. A replacement therapy in Fabry\u2019s disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"6278_CR3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke 40:788\u2013794","journal-title":"Stroke"},{"key":"6278_CR4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"6278_CR5","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","volume":"366","author":"A Rolfs","year":"2005","unstructured":"Rolfs A, B\u00f6ttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, L\u00f6hr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366:1794\u20131796","journal-title":"Lancet"},{"key":"6278_CR6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clineuro.2007.03.008","volume":"109","author":"R Brouns","year":"2007","unstructured":"Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, Mehta A, Timmerman T, Vincet MF, De Deyn PP (2007) Middleheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 109:479\u2013484","journal-title":"Clin Neurol Neurosurg"},{"key":"6278_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/STROKEAHA.109.558320","volume":"41","author":"MA Wozniak","year":"2010","unstructured":"Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, Desnick RJ (2010) Frequency of unrecognized Fabry disease among young European\u2013American and African\u2013American men with first ischemic stroke. Stroke 41:78\u201381","journal-title":"Stroke"},{"key":"6278_CR8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/STROKEAHA.109.570499","volume":"41","author":"MV Baptista","year":"2010","unstructured":"Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, Silva FA, Tuna A, Rodrigues M, Ferreira C, Pinto AA, Leit\u00e3o A, Gabriel JP, Calado S, Oliveira JP, Ferro JM, PORTYSTROKE Investigators (2010) Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study\u2014screening genetic conditions in Portuguese young stroke patients. Stroke 41:431\u2013436","journal-title":"Stroke"},{"key":"6278_CR9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","volume":"41","author":"R Brouns","year":"2010","unstructured":"Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, Redondo P, Hemelsoet D, Fumal A, Jeangette S, Verslegers W, Baker R, Hughes D, De Deyn PP, BeFaS Investigators (2010) Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 41:863\u2013868","journal-title":"Stroke"},{"key":"6278_CR10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Twickler TB, Aerts JMFG, Linthorst GE, Wijburg FA, Hollak CEM (2010) Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metabol 99:99\u2013108","journal-title":"Mol Genet Metabol"},{"key":"6278_CR11","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) \u03b1-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733\u20133774"},{"key":"6278_CR12","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry\u2019s disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"6278_CR13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86\u201392","journal-title":"Acta Paediatr"},{"key":"6278_CR14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"6278_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, Pashos CL (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317\u2013327","journal-title":"Qual Life Res"},{"key":"6278_CR16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","volume":"30","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68\u201378","journal-title":"J Inherit Metab Dis"},{"key":"6278_CR17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"6278_CR18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","volume":"122","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65\u201377","journal-title":"Pharmacol Ther"},{"key":"6278_CR19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","volume":"33","author":"Df Moore","year":"2002","unstructured":"Moore Df, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, Charria-Ortiz G, Ferri R, Arai AE, Brady RO, Schiffmann R (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33:525\u2013531","journal-title":"Stroke"},{"key":"6278_CR20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00868342","volume":"241","author":"RP Grewal","year":"1994","unstructured":"Grewal RP (1994) Stroke in Fabry\u2019s disease. J Neurol 241:153\u2013156","journal-title":"J Neurol"},{"key":"6278_CR21","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1212\/01.wnl.0000173030.70057.eb","volume":"65","author":"A Fellgiebel","year":"2005","unstructured":"Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P (2005) White matter lesion severity in male and female patients with Fabry disease. Neurology 65:600\u2013602","journal-title":"Neurology"},{"key":"6278_CR22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"3","author":"M Ries","year":"2006","unstructured":"Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL, Pastores G, Lien YH, Kampmann C, Brady RO, Beck M, Schiffmann R (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 3:924\u2013932","journal-title":"Pediatrics"},{"key":"6278_CR23","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S, Sorensen S, Wilcox W, Desnick R (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102\u20132111","journal-title":"Nephrol Dial Transplant"},{"key":"6278_CR24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ana.410400105","volume":"40","author":"P Mitsias","year":"1996","unstructured":"Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry\u2019s disease. Ann Neurol 40:8\u201317","journal-title":"Ann Neurol"},{"key":"6278_CR25","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswani U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-plassman G (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19:782\u2013787","journal-title":"Am J Hypertens"},{"key":"6278_CR26","doi-asserted-by":"crossref","first-page":"c43","DOI":"10.1159\/000320903","volume":"118","author":"G Jain","year":"2011","unstructured":"Jain G, Warnock DG (2011) Blood pressure, proteinuria and nephropathy in Fabry disease. Nephron Clin Pract 118:c43\u2013c48","journal-title":"Nephron Clin Pract"},{"key":"6278_CR27","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1212\/WNL.50.6.1746","volume":"50","author":"KE Crutchfield","year":"1998","unstructured":"Crutchfield KE, Patronas NJ, Dambrosia JM, Frei KP, Benerjee TK, Barton NW, Schiffmann R et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746\u20131749","journal-title":"Neurology"},{"issue":"5","key":"6278_CR28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","volume":"251","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendel T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with fabry disease. J Neurol 251(5):564\u2013570","journal-title":"J Neurol"},{"key":"6278_CR29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jns.2007.01.053","volume":"257","author":"DF Moore","year":"2007","unstructured":"Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258\u2013263","journal-title":"J Neurol Sci"},{"issue":"13","key":"6278_CR30","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","volume":"104","author":"DF Moore","year":"2001","unstructured":"Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, Pease-Fye M, Ferri R, Brady RO, Herscovitch P, Schiffmann R (2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104(13):1506\u20131512","journal-title":"Circulation"},{"issue":"5","key":"6278_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","volume":"84","author":"S Gupta","year":"2005","unstructured":"Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 84(5):261\u2013268","journal-title":"Medicine"},{"issue":"2","key":"6278_CR32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","volume":"47","author":"T DeGraba","year":"2000","unstructured":"DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, McCarron R, Schiffmann R (2000) Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 47(2):229\u2013233","journal-title":"Ann Neurol"},{"issue":"1","key":"6278_CR33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ajh.2830220110","volume":"22","author":"T Igarashi","year":"1986","unstructured":"Igarashi T, Sakuraba H, Suzuki Y (1986) Activation of platelet function in Fabry\u2019s disease. Am J Hematol 22(1):63\u201367","journal-title":"Am J Hematol"},{"key":"6278_CR34","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.amjcard.2010.07.016","volume":"106","author":"IF Gambarin","year":"2010","unstructured":"Gambarin IF, Disabella E, Narula J, Diegoli M, Grasso M, Serio A, Favalli V, Agozzino M, Tavazzi L, Fraser AG, Arbustini E (2010) When should cardiologists suspect Anderson-Fabry disease. Am J Cardiol 106:1492\u20131499","journal-title":"Am J Cardiol"},{"key":"6278_CR35","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","volume":"24","author":"JC Moon","year":"2003","unstructured":"Moon JC, Sachdev B, Elkington AG, Mc Kenna WJ, Metha A, Pennell DJ, Leed PJ, Elliot PM (2003) Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 24:2151\u20132155","journal-title":"Eur Heart J"},{"key":"6278_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR (2006) Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"6278_CR37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10545-009-1156-2","volume":"32","author":"JM Politei","year":"2009","unstructured":"Politei JM (2009) Can we use statins to prevent stroke in Fabry disease? J Inherit Metab Dis 32:481\u2013487","journal-title":"J Inherit Metab Dis"},{"key":"6278_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1651-2227.2002.tb03112.x","volume":"91","author":"K Demuth","year":"2002","unstructured":"Demuth K, Germain DP (2002) Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr Suppl 91:57\u201361","journal-title":"Acta Paediatr Suppl"},{"key":"6278_CR39","author":"T Zenone","year":"(2011","unstructured":"Zenone T, Chan V ((2011) Young woman with recurrent ischemic strokes diagnosed as Fabry disease: lessons learned from a case report. Clin Neurol Neurosurg. doi: 10.1016\/j.clineuro.2011.02.012","journal-title":"Clin Neurol Neurosurg"},{"key":"6278_CR40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","volume":"11","author":"O Lidove","year":"2010","unstructured":"Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A (2010) Effects of enzyme replacement therapy in Fabry disease\u2014a comprehensive review of the medical literature. Genet Med 11:668\u2013679","journal-title":"Genet Med"},{"key":"6278_CR41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345\u2013354","journal-title":"Nephrol Dial Transplant"},{"key":"6278_CR42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"6278_CR43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","volume":"27","author":"L Jardim","year":"2004","unstructured":"Jardim L, Vedolin L, Schwartz VD, Burin MG, Cecchin C, Kalakun L, Matte U, Aesse F, Pitta-Pinheiro C, Marconato J, Giugliani R (2004) CNS involvement in Fabry disease: clinical and imaging studies before and after 12\u00a0months of enzyme replacement therapy. J Inherit Metab Dis 27:229\u2013240","journal-title":"J Inherit Metab Dis"},{"key":"6278_CR44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2008.12.028","volume":"279","author":"M Yamadera","year":"2009","unstructured":"Yamadera M, Yokoe M, Beck G, Mihara M, Oe H, Yamamoto Y, Sakoda S (2009) Amelioration of white-matter lesions in a patient with Fabry disease. J Neurol Sci 279:118\u2013120","journal-title":"J Neurol Sci"},{"issue":"1","key":"6278_CR45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","volume":"42","author":"KL Furie","year":"2011","unstructured":"Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D (2011) American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association\/american stroke association. Stroke 42(1):227\u2013276","journal-title":"Stroke"},{"key":"6278_CR46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpeds.2005.03.004","volume":"147","author":"MA Cabrera-Salazar","year":"2005","unstructured":"Cabrera-Salazar MA, O\u2019Rourke E, Charria-Ortiz G, Barranger JA (2005) Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Pediatr 147:102\u2013105","journal-title":"J Pediatr"},{"key":"6278_CR47","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/jnnp.2006.112987","volume":"78","author":"J Albrecht","year":"2007","unstructured":"Albrecht J, Dellani PR, M\u00fcller MJ, Schermuly I, Beck M, Stoeter P, Gerhard A, Fellgiebel A (2007) Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry 78:964\u2013969","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6278_CR48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.brainresbull.2003.09.021","volume":"62","author":"DF Moore","year":"2003","unstructured":"Moore DF, Altarescu G, BArker WC, Patronas NJ, Herscovitch P, Schiffmann R (2003) White matter lesions in Fabry disease occur in prior selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 62:231\u2013240","journal-title":"Brain Res Bull"},{"key":"6278_CR49","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, Aerts JM, Hirth A, Hollak CE (2007) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2\u00a0mg\/kg. PLoS One 2:e598","journal-title":"PLoS One"},{"issue":"2","key":"6278_CR50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1468-1331.2010.03155.x","volume":"18","author":"I Schermuly","year":"2011","unstructured":"Schermuly I, M\u00fcller MJ, M\u00fcller KM, Albrecht J, Keller I, Yakushev I, Beck M, Fellgiebel A (2011) Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol 18(2):347\u2013353","journal-title":"Eur J Neurol"},{"issue":"2","key":"6278_CR51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.nrl.0000187495.16824.a6","volume":"12","author":"JM Politei","year":"2006","unstructured":"Politei JM, Capizzano AA (2006) Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist 12(2):103\u2013105","journal-title":"Neurologist"},{"issue":"3","key":"6278_CR52","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/jnnp.2003.014910","volume":"75","author":"M O\u2019Sullivan","year":"2004","unstructured":"O\u2019Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS (2004) Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 75(3):441\u2013447","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"6278_CR53","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00415-008-0661-9","volume":"255","author":"M Viana-Baptista","year":"2008","unstructured":"Viana-Baptista M, Bugalho P, Jord\u00e3o C, Ferreira N, Ferreira A, Forjaz Secca M, Esperan\u00e7a-Pina JA, Ferro JM (2008) Cognitive function correlates with frontal white matter apparent diffusion coefficients in patients with leukoaraiosis. J Neurol 255(3):360\u2013366","journal-title":"J Neurol"},{"key":"6278_CR54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"6278_CR55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1212\/01.wnl.0000338566.54190.8a","volume":"72","author":"A Fellgiebel","year":"2009","unstructured":"Fellgiebel A, Keller I, Marin D, M\u00fcller MJ, Schermuly I, Yakushev I, Albrecht J, Bellh\u00e4user H, Kinateder M, Beck M, Stoeter P (2009) Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology 72(1):63\u201368","journal-title":"Neurology"},{"key":"6278_CR56","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","volume":"79","author":"S Buechner","year":"2008","unstructured":"Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, Mignani R, Parini R, Di Vito R, Giordano GP, Simonelli P, Siciliano G, Borsini W (2008) Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249\u20131254","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6278_CR57","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1212\/WNL.52.8.1663","volume":"52","author":"G Tedeschi","year":"1999","unstructured":"Tedeschi G, Bonavita S, Banerjee TK, Virta A, Schiffmann R (1999) Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 52:1663\u20131667","journal-title":"Neurology"},{"issue":"4","key":"6278_CR58","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00415-005-0020-z","volume":"253","author":"S Marino","year":"2006","unstructured":"Marino S, Borsini W, Buchner S, Mortilla M, Stromillo ML, Battaglini M, Giorgio A, Bramanti P, Federico A, De Stefano N (2006) Diffuse structural and metabolic brain changes in Fabry disease. J Neurol 253(4):434\u2013440","journal-title":"J Neurol"},{"issue":"1\u20132","key":"6278_CR59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jns.2010.08.037","volume":"299","author":"EB Ringelstein","year":"2010","unstructured":"Ringelstein EB, Kleffner I, Dittrich R, Kuhlenb\u00e4umer G, Ritter MA (2010) Hereditary and non-hereditary microangiopathies in the young. An up-date. J Neurol Sci 299(1\u20132):81\u201385","journal-title":"J Neurol Sci"},{"issue":"3","key":"6278_CR60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000322558","volume":"31","author":"A Fellgiebel","year":"2011","unstructured":"Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, B\u00f6ttcher T, Fazekas F, Rolfs A (2011) Basilar artery diameter is a potential screening tool for fabry disease in young stroke patients. Cerebrovasc Dis 31(3):294\u2013299","journal-title":"Cerebrovasc Dis"},{"key":"6278_CR61","first-page":"1096","volume":"24","author":"DF Moore","year":"2003","unstructured":"Moore DF, Ye F, Schiffmann R, Butman JA (2003) Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 24:1096\u20131101","journal-title":"Am J Neuroradiol"},{"key":"6278_CR62","first-page":"916","volume":"24","author":"J Takanashi","year":"2003","unstructured":"Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S (2003) T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. Am J Neuroradiol 24:916\u2013921","journal-title":"Am J Neuroradiol"},{"key":"6278_CR63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00415-008-0786-x","volume":"255","author":"AP Burlina","year":"2008","unstructured":"Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, Burlina A, Lidove O (2008) The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol 255:738\u2013744","journal-title":"J Neurol"},{"issue":"Suppl 3","key":"6278_CR64","first-page":"III\/13","volume":"254","author":"R Manara","year":"2007","unstructured":"Manara R, Ginsberg L, Severino S, Valentine AR, Kendall B, Clarke JTR, Mehta A, Burlina AP (2007) White matter and pulvinar signal abnormalities in Fabry disease: data from the Fabry Outcome Survey (FOS). J Neurol 254(Suppl 3):III\/13","journal-title":"J Neurol"},{"issue":"4","key":"6278_CR65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","volume":"47","author":"GE Linthorst","year":"2010","unstructured":"Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2010) Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 47(4):217\u2013222","journal-title":"J Med Genet"},{"key":"6278_CR66","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an underrecognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338\u2013346","journal-title":"Ann Intern Med"},{"key":"6278_CR67","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/jnnp.2008.158790","volume":"12","author":"SM Gregoire","year":"2009","unstructured":"Gregoire SM, Brown MM, Collas DM, Jacob P, Lachmann RH, Werring DJ (2009) Posterior circulation strokes without systemic involvement as the presenting feature of Fabry disease. J Neurol Neurosurg Psychiatry 12:1414\u20131416","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"6278_CR68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000322153","volume":"31","author":"A Rolfs","year":"2011","unstructured":"Rolfs A, Martus P, Heuschmann PU, Grittner U, Holzhausen M, Tatlisumak T, B\u00f6ttcher T, Fazekas F, Enzinger C, Ropele S, Schmidt R, Riess O, Norrving B (2011) Protocol and methodology of the stroke in young Fabry patients (Sifap1) study: a prospective multicenter European study of 5,024 young stroke patients aged 18\u201355\u00a0years. Cerebrovasc Dis 31(3):253\u2013262","journal-title":"Cerebrovasc Dis"},{"key":"6278_CR69","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1161\/STROKEAHA.110.593814","volume":"42","author":"R Brouns","year":"2011","unstructured":"Brouns R, Thijs V, De Eyskens F, Deyn PP (2011) Response to letter regarding Belgian Fabry study: Prevalence of Fabry disease in a cohort of 1,000 young patients with cerebrovascular disease. Stroke 42:e6\u2013e7","journal-title":"Stroke"},{"key":"6278_CR70","unstructured":"Baumgartner R (2011) Prevalence of Fabry disease in ischemic stroke of unknown etiology. Available at: http:\/\/www.researchportal.ch\/unizh\/p8126.htm . Accessed June 2011"},{"key":"6278_CR71","unstructured":"Clavelou P (2011) Fabry: National Initiative of Screening (FIND). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00484549?term=fabry&rank=10 . Accessed June 2011"},{"key":"6278_CR72","doi-asserted-by":"crossref","unstructured":"Baptista MV, PORTYSTROKE investigators. 2011 Response to Letter Regarding Article, \u201cMutations of the GLA Gene in Young Patients With Stroke: The PORTYSTROKE Study-Screening Genetic Conditions in PORTuguese Young STROKE Patients\u201d. Stroke; 42: e9","DOI":"10.1161\/STROKEAHA.110.601963"},{"key":"6278_CR73","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","volume":"80","author":"R Froissart","year":"2003","unstructured":"Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I (2003) Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 80:307\u2013314","journal-title":"Mol Genet Metab"},{"key":"6278_CR74","first-page":"336","volume":"125","author":"YH Chien","year":"2009","unstructured":"Chien YH (2009) Novel human pathological mutations: gene symbol: GLA disease: Fabry disease. Hum Genet 125:336","journal-title":"Hum Genet"},{"key":"6278_CR75","doi-asserted-by":"crossref","unstructured":"Wozniak MA, Kittner SJ, Cole JW, Stern B, Tuhrim S, Desnick RJ (2011) Response to letter regarding frequency of unrecognized Fabry disease among young European\u2013American and African\u2013American men with first ischemic stroke. Stroke 42: e8","DOI":"10.1161\/STROKEAHA.110.593830"},{"key":"6278_CR76","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1161\/STROKEAHA.110.591776","volume":"42","author":"O Lidove","year":"2011","unstructured":"Lidove O, Joly D, Touze\u2019 E (2011) Letter regarding Brouns et al. Baptista et al. and Wozniak et al. Stroke 42:e4\u2013e5","journal-title":"Stroke"},{"key":"6278_CR77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/01.STR.24.3.362","volume":"24","author":"A Carolei","year":"1993","unstructured":"Carolei A, Marini C, Ferranti E, Frontoni M, Prencipe M, Fieschi C (1993) A prospective study of cerebral ischemia in the young. Analysis of pathogenic determinants. Stroke 24:362\u2013367","journal-title":"Stroke"},{"key":"6278_CR78","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/01.STR.28.9.1702","volume":"28","author":"B Kristensen","year":"1997","unstructured":"Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T (1997) Epidemiology and etiology of stroke in young adults aged 18 to 44\u00a0years in northern Sweden. Stroke 28:1702\u20131709","journal-title":"Stroke"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-011-6278-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-011-6278-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:22:56Z","timestamp":1559056976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-011-6278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["6278"],"URL":"https:\/\/doi.org\/10.1007\/s00415-011-6278-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]}}}